Selected starting points for reading the evidence. These summaries cover selected studies; other library entries have their own source dates and have not all been re-reviewed.
Read the study findings and primary sources
Semaglutide: cardiovascular outcomes in SELECT
SELECT enrolled 17,604 adults aged 45 or older with a body mass index of at least 27, established cardiovascular disease and no diabetes history. Participants received injectable semaglutide or placebo alongside standard care.
Over a mean 39.8 months of follow-up, the first cardiovascular death, nonfatal heart attack or nonfatal stroke occurred in 569/8,803 participants (6.5%) with semaglutide versus 701/8,801 (8.0%) with placebo. The absolute difference was about 1.5 percentage points; the hazard ratio was 0.80 (95% CI 0.72–0.90). Adverse events led to permanent treatment discontinuation in 16.6% versus 8.2%.
FDA added a cardiovascular-risk reduction indication for Wegovy injection in March 2024 for adults with established cardiovascular disease and overweight or obesity, alongside a reduced-calorie diet and increased physical activity. This combined trial outcome does not establish the same benefit for each component or longer life in healthy adults. It is not a complete safety guide.
SELECT primary report abstract (NEJM, 2023) · Trial registry and results · FDA indication and safety information (2024)
Established evidence added to this library November 16, 2026; not a newly reported trial. SELECT was funded by Novo Nordisk.
Cerebrolysin: not FDA approved
Cerebrolysin is not FDA approved. Its manufacturer states that it is not approved for sale or distribution in the United States. A 2020 FDA warning letter also identifies Cerebrolysin among substances that were not components of FDA-approved human drugs. Authorization in another country is not FDA approval.
Manufacturer notice to U.S. visitors · FDA warning letter (2020)
Regulatory label corrected November 16, 2026. This status note is not an assessment of efficacy or a treatment recommendation.
Retatrutide: weight loss is not an approval decision
In TRIUMPH-1, 2,339 adults with obesity, or overweight with a weight-related complication, without diabetes were randomized to retatrutide or placebo. At 80 weeks, the 12 mg study group had an average body-weight change of −25.0%, compared with −3.9% with placebo, using the treatment-regimen analysis, which includes treatment discontinuation. The 28.3% headline uses a different efficacy estimand and is not interchangeable. Gastrointestinal adverse events were common. Trial doses identify study groups; they are not instructions for use.
Retatrutide remains investigational. FDA states that it is not a component of an approved drug and cannot be used in compounding under federal law. These results do not establish longer life or benefit for healthy adults seeking longevity treatment.
TRIUMPH-1 paper (NEJM, September 2026) · FDA guidance · Full retatrutide evidence guide and estimands
The knee-osteoarthritis update covers the November 8 report’s pain, patient-reported function and safety findings, including its source limitations.
BELIEVE: body composition and muscle function differ
BELIEVE randomized 507 adults with obesity, or overweight with an obesity-related complication, excluding diabetes. Bimagrumab is an antibody that blocks activin type II receptors, affecting myostatin and activin signaling; it is broader than a direct myostatin inhibitor. At 48 weeks, the treatment-regimen analysis estimated lean-mass changes of −1.3 kg with bimagrumab 30 mg/kg plus semaglutide 2.4 mg versus −3.9 kg with semaglutide 2.4 mg alone. Fat-mass changes were −15.6 kg versus −9.6 kg.
These trial groups do not provide a treatment recommendation. DXA lean mass is not a direct measure of strength. The study does not establish consistent functional improvement, fracture prevention or longer life. Reported adverse events included muscle spasms, diarrhea and acne; semaglutide treatment was open label.
BELIEVE paper (Nature Medicine, March 2026) · Full BELIEVE evidence guide and withdrawal findings
COURAGE: read the regimens separately
The November 11 published report distinguishes lean-mass findings from functional benefit. Dose-specific uncertainty and separate three-drug safety findings matter when interpreting the study.
COURAGE published abstract (The Lancet, November 2026) · Results, harms and evidence limits
Educational summaries prepared with AI assistance; no article-specific physician review is claimed. Discuss treatment questions with a licensed clinician. How Annume handles evidence.